TRAIL receptor I (DR4) polymorphisms C626G and A683C are associated with an increased risk for hepatocellular carcinoma (HCC) in HCV-infected patients.
about
Death receptor (DR4) haplotypes are associated with increased susceptibility of gallbladder carcinoma in north Indian populationGenetic association between TRAIL-R1 Thr209Arg and cancer susceptibility.TNFRSF10B polymorphisms and haplotypes associated with increased risk of death in non-small cell lung cancer.Cellular and molecular mechanisms of hepatocellular carcinoma: an update.Apoptotic mediators in patients with severe and non-severe dengue from Brazil.Evaluation of TRAIL receptor 1 (DR4) Polymorphisms C626G and A683C as risk factors of hepatocellular carcinoma.
P2860
TRAIL receptor I (DR4) polymorphisms C626G and A683C are associated with an increased risk for hepatocellular carcinoma (HCC) in HCV-infected patients.
description
2012 nî lūn-bûn
@nan
2012 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
2012 թվականի մարտին հրատարակված գիտական հոդված
@hy
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
name
TRAIL receptor I (DR4) polymor ...... HCC) in HCV-infected patients.
@ast
TRAIL receptor I (DR4) polymor ...... HCC) in HCV-infected patients.
@en
TRAIL receptor I
@nl
type
label
TRAIL receptor I (DR4) polymor ...... HCC) in HCV-infected patients.
@ast
TRAIL receptor I (DR4) polymor ...... HCC) in HCV-infected patients.
@en
TRAIL receptor I
@nl
prefLabel
TRAIL receptor I (DR4) polymor ...... HCC) in HCV-infected patients.
@ast
TRAIL receptor I (DR4) polymor ...... HCC) in HCV-infected patients.
@en
TRAIL receptor I
@nl
P2093
P2860
P50
P356
P1433
P1476
TRAIL receptor I (DR4) polymor ...... (HCC) in HCV-infected patients
@en
P2093
Andreas Glässner
Franziska Wolter
Jacob Nattermann
Katarina Riesner
Marianne Eisenhardt
Tilman Sauerbruch
Tobias Müller
Ulrich Spengler
P2860
P2888
P356
10.1186/1471-2407-12-85
P407
P577
2012-03-08T00:00:00Z
P5875
P6179
1053595037